Literature DB >> 11097604

Juxtapapillary capillary hemangiomas. Clinical features and visual acuity outcomes.

C M McCabe1, H W Flynn, C L Shields, J A Shields, C D Regillo, H R McDonald, M H Berrocal, J D Gass, W F Mieler.   

Abstract

OBJECTIVE: To describe the clinical features, association with von Hippel-Lindau (VHL) disease and visual acuity outcomes of patients with a juxtapapillary capillary hemangioma.
DESIGN: Retrospective observational case series. PARTICIPANTS: Seventy-two eyes of 68 patients identified with a juxtapapillary capillary hemangioma. Follow-up data of at least 6 months duration were available for 60 eyes.
METHODS: A retrospective chart review of patients diagnosed with a juxtapapillary capillary hemangioma examined at four medical centers. MAIN OUTCOME MEASURES: Age at diagnosis, visual acuity (VA) at first examination and at last follow-up, tumor growth pattern and location, associated clinical features, type of treatment, association with VHL, and presence of peripheral hemangiomas were recorded for each patient.
RESULTS: On initial examination, VA was >/=20/40 in 43 of 70 eyes (61%) and was >/=20/200 in 60 eyes (86%). At an average follow-up of 5.4 years (range, 0.5-19 years), VA of >/=20/40 was achieved in 21 eyes (35%) and >/=20/200 in 33 eyes (55%). Patients with VHL had poorer initial VA (48% vs. 70% with VA >/=20/40, and 74% vs. 93% with VA >/=20/200) and final VA (26% vs. 41% with VA >/=20/40, and 39% vs. 65% with VA >/=20/200) compared with patients without VHL. Patients with VHL more commonly were seen at an earlier age (average, 20 vs. 44 years, P: < 0.001), with bilateral (17% vs. 0%), and/or peripheral (39% vs. 0%) (P: < 0.001) tumors that more often had an endophytic growth pattern (63% vs. 22%, P: = 0.001) compared with patients without VHL. Patients selected for laser treatment generally had poorer initial (52% vs. 74% with VA >/=20/40, 79% vs. 96% with VA >/=20/200) and final VAs (18% vs. 56% with VA >/=20/40, 45% vs. 67% with VA >/=20/200) compared with patients not treated with laser.
CONCLUSIONS: On long-term follow-up of patients with a juxtapapillary capillary hemangioma, the VA generally worsens. Patients with VHL and a juxtapapillary hemangioma more often present at a younger age, have tumors with an endophytic growth pattern, and have bilateral, multiple tumors. Treatment with laser photocoagulation results in variable VA outcomes.

Entities:  

Mesh:

Year:  2000        PMID: 11097604     DOI: 10.1016/s0161-6420(00)00422-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  22 in total

1.  Juxtapapillary capillary hemangioma treated by intravitreal injection of bevacizumab combined with posterior subtenon injection of triamcinolone acetonide.

Authors:  Noriko Toyokawa; Hideya Kimura; Shinichiro Kuroda
Journal:  Jpn J Ophthalmol       Date:  2010-04-18       Impact factor: 2.447

Review 2.  [Retinal angiomatosis. Ocular manifestation of von Hippel-Lindau disease].

Authors:  B Junker; D Schmidt; H T Agostini
Journal:  Ophthalmologe       Date:  2007-02       Impact factor: 1.059

Review 3.  Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.

Authors:  Chi-Chao Chan; Atif Ben Daniel Collins; Emily Y Chew
Journal:  Retina       Date:  2007-01       Impact factor: 4.256

Review 4.  Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications.

Authors:  Klaus-Martin Kreusel
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype.

Authors:  Pradeep Mettu; Elvira Agrón; Sonia Samtani; Emily Y Chew; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-07       Impact factor: 4.799

6.  Longitudinal Swept-Source OCT Angiography of Juxtapapillary Retinal Capillary Hemangioblastoma.

Authors:  Jonathan F Russell; Yingying Shi; Giovanni Gregori; Philip J Rosenfeld
Journal:  Ophthalmol Retina       Date:  2020-05-08

7.  Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.

Authors:  Chi-Chao Chan; Youn-Soo Lee; Zhengping Zhuang; Joseph Hackett; Emily Y Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2004

8.  Neuro-ophthalmology of von Hippel-Lindau.

Authors:  Eric W Fitz; Steven A Newman
Journal:  Curr Neurol Neurosci Rep       Date:  2004-09       Impact factor: 5.081

9.  Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease.

Authors:  Wai T Wong; Katharine J Liang; Keri Hammel; Hanna R Coleman; Emily Y Chew
Journal:  Ophthalmology       Date:  2008-09-11       Impact factor: 12.079

10.  Intravitreal bevacizumab and feeder vessel laser treatment for a posteriorly located retinal capillary hemangioma.

Authors:  Aniruddha Agarwal; Neha Kumari; Ramandeep Singh
Journal:  Int Ophthalmol       Date:  2016-01-27       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.